| Autor: |
Elliott STC; 1 The Wistar Institute of Anatomy and Biology , Philadelphia, Pennsylvania., Keaton AA; 1 The Wistar Institute of Anatomy and Biology , Philadelphia, Pennsylvania., Chu JD; 1 The Wistar Institute of Anatomy and Biology , Philadelphia, Pennsylvania., Reed CC; 2 Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania., Garman B; 2 Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania., Patel A; 1 The Wistar Institute of Anatomy and Biology , Philadelphia, Pennsylvania., Yan J; 2 Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania., Broderick KE; 2 Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania., Weiner DB; 1 The Wistar Institute of Anatomy and Biology , Philadelphia, Pennsylvania. |
| Abstrakt: |
Influenza A H3N2 viruses circulate globally, leading to substantial morbidity and mortality. Commercially available, antigen-matched influenza vaccines must be updated frequently to match dynamic sequence variability in immune epitopes, especially within viral influenza A H3N2 hemagglutinin (H3). In an effort to create comprehensive immune responses against H3N2, four micro-consensus antigens were designed to mimic the sequence and antigenic diversity of H3. Synthetic plasmid DNA constructs were developed to express each micro-consensus immunogen and combined into a multi-antigen DNA vaccine cocktail, pH3HA. Facilitated delivery of pH3HA via intramuscular electroporation in mice induced comprehensive, potent humoral responses against diverse seasonal H3N2 viruses that circulated between 1968 and the present. Vaccination with pH3HA also induced an antigen-specific cellular cytokine response. Mice immunized with pH3HA were protected against lethal challenge using two distinct H3N2 viruses, highlighting the heterologous protection afforded by synthetic micro-consensus immunogens. These findings warrant further study of the DNA vaccine micro-consensus platform for broad protection against influenza viruses. |
